Amarin Corporation PLC Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa® and Planned ANCHOR Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, March 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/614,111titled "Stable Pharmaceutical Compositions and Methods of Using the Same." This application includes claims intended to protect the proposed Vascepa® (icosapent ethyl) indication based on Amarin's Phase 3 ANCHOR clinical trial results. In late February, Amarin filed a Supplemental New Drug Application for the Vascepa ANCHOR indication with the U.S. Food and Drug Administration (FDA), and expects an FDA action date on the application before the end of 2013.